{"id":920,"date":"2025-12-22T18:38:10","date_gmt":"2025-12-22T18:38:10","guid":{"rendered":"http:\/\/wmtc2006.com\/?p=920"},"modified":"2025-12-22T18:38:10","modified_gmt":"2025-12-22T18:38:10","slug":"no-statistical-differences-at-t1-or-t2-n-26-were-observed","status":"publish","type":"post","link":"https:\/\/wmtc2006.com\/?p=920","title":{"rendered":"\ufeffNo statistical differences at T1 or T2 (n = 26) were observed"},"content":{"rendered":"

\ufeffNo statistical differences at T1 or T2 (n = 26) were observed. effector cells was observed after 12 and 24 months of treatment. CD4+and CD8+T-lymphocyte immune-activation was increased after 24 months of treatment. Higher percentages of CD8+effectors were observed TVB-3166<\/a> in subjects with detectable JCV-DNA. Natalizumab reduces CD49d expression TVB-3166 on CD8+T-lymphocyte memory and effector subsets, limiting their migration to the central nervous system and determining their accumulation in peripheral blood. Impairment of central nervous system immune surveillance and reactivation of latent JCV, can explain the increased risk of PML development in natalizumab-treated RRMS subjects. == Introduction == CD49d is an 4-integrin that associates with 1-integrin to form the very late antigen-4 (VLA-4) or with 7-integrin to form the lymphocyte Peyers patch adhesion molecule (LPAM). VLA-4 controls the migration of mononuclear leukocytes into the central nervous system (CNS) TVB-3166 [15]. Blockade of CD49d with the humanized monoclonal antibody natalizumab suppresses trafficking of inflammatory leukocytes into the CNS [3] and prospects to a significant decrease in the clinical relapse rate of the relapsing-remitting form of multiple sclerosis (RRMS) [6]. Natalizumab is currently the most effective therapy against RRMS [7], however, its therapeutic efficacy is usually clouded by reactivation of the John Cunningham polyomavirus (JCV) and development of progressive multifocal leukoencephalopathy (PML) [8]. JCV infects a large portion of individuals worldwide [9,10] and establishes lifelong prolonged contamination in kidneys, tonsils, bone marrow and CNS [1116]. The Mouse monoclonal to Plasma kallikrein3<\/a> Stratify JCV assay is usually a validated test to measure anti-JCV antibodies in human serum and is currently used to stratify MS patients for higher or lower risk of developing PML [17]. However, due to the occurrence of JCV contamination without the development of detectable antibody responses, additional markers are required in order to appropriately stratify patients. Previous work has shown that natalizumab treatment increases the pool of circulating activated T-cells and other lymphocytes and decreased CD49d surface expression [18]. Therefore, the aim of this study TVB-3166 was to longitudinally assess CD49d expression and CD4+and CD8+T-lymphocyte phenotype alterations in the peripheral blood of natalizumab treated RRMS patients, in relationship with JCV reactivation. == Materials and Methods == == Study populace == 26 subjects diagnosed with RRMS were enrolled at the Department of Neurology and Psychiatry of the University or college of Rome Sapienza between March 2012 and March 2014. Samples were collected before the first natalizumab infusion (T0), 12 and 24 months post-treatment initiation (T1 and T2, respectively). The TVB-3166 therapeutic protocol consisted of administration of 300 mg intravenous natalizumab every 4 weeks. A washout period of at least 1 month for immunomodulatory drugs and 6 months for immunosuppressive drugs was mandatory before the initial natalizumab administration. All patients regularly underwent a complete physical and neurological examination and neurological disability was assessed by the Expanded Disability Status Level (EDSS) score. Sixteen healthy donors (HD), age and sex matched with the RRMS patients, were enrolled as a control group. This study was approved by the Ethics Committee of Policlinico Umberto I of Rome (protocol number 130\/13). All study participants fulfilled the Italian Agency of Drug (AIFA) criteria for natalizumab (Tysabri) treatment and provided a written informed consent. == Sample collection == Peripheral blood was collected in 1 ethylenediamine tetra-acetic acid (EDTA) tube, 1 heparin tube and 1 tube without anticoagulants at T0, T1 and T2. Plasma was obtained from EDTA whole blood after centrifugation and stored at -80C until use. PBMCs were isolated from EDTA whole blood via Ficoll Hypaque (Amersham Biosciences, Uppsala, Sweden) density gradient centrifugation. The number of viable leukocytes was determined by trypan blue exclusion. PBMCs were stored at -80C until use. Serum was obtained from blood collected without anticoagulants and stored at -80C until use. Urine was collected in sterile screw-cap containers and stored at -80C until use. Heparin whole blood was utilized for multi-color circulation cytometry immunophenotyping. == Detection of JCV antibodies == The presence of JCV specific antibodies in the serum of patients at baseline (n = 16), 12 and 24 months post-natalizumab treatment (n = 26) was assessed using the Stratify JCVassay, which is a two-step enzyme-linked immunosorbent.<\/p>\n","protected":false},"excerpt":{"rendered":"

\ufeffNo statistical differences at T1 or T2 (n = 26) were observed. effector cells was observed after 12 and 24 months of treatment. CD4+and CD8+T-lymphocyte […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[41],"tags":[],"class_list":["post-920","post","type-post","status-publish","format-standard","hentry","category-heparanase"],"yoast_head":"\n\ufeffNo statistical differences at T1 or T2 (n = 26) were observed - Discovery and characterization of Histamine-2 Receptor Antagonists<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/wmtc2006.com\/?p=920\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\ufeffNo statistical differences at T1 or T2 (n = 26) were observed - Discovery and characterization of Histamine-2 Receptor Antagonists\" \/>\n<meta property=\"og:description\" content=\"\ufeffNo statistical differences at T1 or T2 (n = 26) were observed. effector cells was observed after 12 and 24 months of treatment. CD4+and CD8+T-lymphocyte [...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/wmtc2006.com\/?p=920\" \/>\n<meta property=\"og:site_name\" content=\"Discovery and characterization of Histamine-2 Receptor Antagonists\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-22T18:38:10+00:00\" \/>\n<meta name=\"author\" content=\"wpadmin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"wpadmin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/wmtc2006.com\\\/?p=920#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/wmtc2006.com\\\/?p=920\"},\"author\":{\"name\":\"wpadmin\",\"@id\":\"http:\\\/\\\/wmtc2006.com\\\/#\\\/schema\\\/person\\\/5a1d916d8ed9c89b34ac45c96f81e776\"},\"headline\":\"\ufeffNo statistical differences at T1 or T2 (n = 26) were observed\",\"datePublished\":\"2025-12-22T18:38:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/wmtc2006.com\\\/?p=920\"},\"wordCount\":665,\"articleSection\":[\"Heparanase\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/wmtc2006.com\\\/?p=920\",\"url\":\"https:\\\/\\\/wmtc2006.com\\\/?p=920\",\"name\":\"\ufeffNo statistical differences at T1 or T2 (n = 26) were observed - Discovery and characterization of Histamine-2 Receptor Antagonists\",\"isPartOf\":{\"@id\":\"http:\\\/\\\/wmtc2006.com\\\/#website\"},\"datePublished\":\"2025-12-22T18:38:10+00:00\",\"author\":{\"@id\":\"http:\\\/\\\/wmtc2006.com\\\/#\\\/schema\\\/person\\\/5a1d916d8ed9c89b34ac45c96f81e776\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/wmtc2006.com\\\/?p=920#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/wmtc2006.com\\\/?p=920\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/wmtc2006.com\\\/?p=920#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"http:\\\/\\\/wmtc2006.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\ufeffNo statistical differences at T1 or T2 (n = 26) were observed\"}]},{\"@type\":\"WebSite\",\"@id\":\"http:\\\/\\\/wmtc2006.com\\\/#website\",\"url\":\"http:\\\/\\\/wmtc2006.com\\\/\",\"name\":\"Discovery and characterization of Histamine-2 Receptor Antagonists\",\"description\":\"Just another WordPress site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"http:\\\/\\\/wmtc2006.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"http:\\\/\\\/wmtc2006.com\\\/#\\\/schema\\\/person\\\/5a1d916d8ed9c89b34ac45c96f81e776\",\"name\":\"wpadmin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e57206ca88c051844b618224f501afdd8e9328b238000fd2f37bf30c03bcff14?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e57206ca88c051844b618224f501afdd8e9328b238000fd2f37bf30c03bcff14?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e57206ca88c051844b618224f501afdd8e9328b238000fd2f37bf30c03bcff14?s=96&d=mm&r=g\",\"caption\":\"wpadmin\"},\"sameAs\":[\"http:\\\/\\\/wmtc2006.com\"],\"url\":\"https:\\\/\\\/wmtc2006.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\ufeffNo statistical differences at T1 or T2 (n = 26) were observed - Discovery and characterization of Histamine-2 Receptor Antagonists","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/wmtc2006.com\/?p=920","og_locale":"en_US","og_type":"article","og_title":"\ufeffNo statistical differences at T1 or T2 (n = 26) were observed - Discovery and characterization of Histamine-2 Receptor Antagonists","og_description":"\ufeffNo statistical differences at T1 or T2 (n = 26) were observed. effector cells was observed after 12 and 24 months of treatment. CD4+and CD8+T-lymphocyte [...]","og_url":"https:\/\/wmtc2006.com\/?p=920","og_site_name":"Discovery and characterization of Histamine-2 Receptor Antagonists","article_published_time":"2025-12-22T18:38:10+00:00","author":"wpadmin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"wpadmin","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/wmtc2006.com\/?p=920#article","isPartOf":{"@id":"https:\/\/wmtc2006.com\/?p=920"},"author":{"name":"wpadmin","@id":"http:\/\/wmtc2006.com\/#\/schema\/person\/5a1d916d8ed9c89b34ac45c96f81e776"},"headline":"\ufeffNo statistical differences at T1 or T2 (n = 26) were observed","datePublished":"2025-12-22T18:38:10+00:00","mainEntityOfPage":{"@id":"https:\/\/wmtc2006.com\/?p=920"},"wordCount":665,"articleSection":["Heparanase"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/wmtc2006.com\/?p=920","url":"https:\/\/wmtc2006.com\/?p=920","name":"\ufeffNo statistical differences at T1 or T2 (n = 26) were observed - Discovery and characterization of Histamine-2 Receptor Antagonists","isPartOf":{"@id":"http:\/\/wmtc2006.com\/#website"},"datePublished":"2025-12-22T18:38:10+00:00","author":{"@id":"http:\/\/wmtc2006.com\/#\/schema\/person\/5a1d916d8ed9c89b34ac45c96f81e776"},"breadcrumb":{"@id":"https:\/\/wmtc2006.com\/?p=920#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/wmtc2006.com\/?p=920"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/wmtc2006.com\/?p=920#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"http:\/\/wmtc2006.com\/"},{"@type":"ListItem","position":2,"name":"\ufeffNo statistical differences at T1 or T2 (n = 26) were observed"}]},{"@type":"WebSite","@id":"http:\/\/wmtc2006.com\/#website","url":"http:\/\/wmtc2006.com\/","name":"Discovery and characterization of Histamine-2 Receptor Antagonists","description":"Just another WordPress site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"http:\/\/wmtc2006.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"http:\/\/wmtc2006.com\/#\/schema\/person\/5a1d916d8ed9c89b34ac45c96f81e776","name":"wpadmin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/e57206ca88c051844b618224f501afdd8e9328b238000fd2f37bf30c03bcff14?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e57206ca88c051844b618224f501afdd8e9328b238000fd2f37bf30c03bcff14?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e57206ca88c051844b618224f501afdd8e9328b238000fd2f37bf30c03bcff14?s=96&d=mm&r=g","caption":"wpadmin"},"sameAs":["http:\/\/wmtc2006.com"],"url":"https:\/\/wmtc2006.com\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/wmtc2006.com\/index.php?rest_route=\/wp\/v2\/posts\/920","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wmtc2006.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wmtc2006.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/wmtc2006.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/wmtc2006.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=920"}],"version-history":[{"count":1,"href":"https:\/\/wmtc2006.com\/index.php?rest_route=\/wp\/v2\/posts\/920\/revisions"}],"predecessor-version":[{"id":921,"href":"https:\/\/wmtc2006.com\/index.php?rest_route=\/wp\/v2\/posts\/920\/revisions\/921"}],"wp:attachment":[{"href":"https:\/\/wmtc2006.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=920"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wmtc2006.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=920"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wmtc2006.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=920"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}